Ginkgo Bioworks Holdings Return on Tangible Equity 2020-2022 | DNA

Current and historical return on tangible equity values for Ginkgo Bioworks Holdings (DNA) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Ginkgo Bioworks Holdings Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-12-31 $-2.11B $1.57B -140.47%
2022-09-30 $-3.53B $1.36B -237.07%
2022-06-30 $-2.96B $1.50B -192.03%
2022-03-31 $-2.35B $1.57B -200.68%
2021-12-31 $-1.83B $1.52B -235.27%
2021-06-30 $-0.15B $0.01B -6160.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.549B $0.478B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $140.576B 8.70
GSK (GSK) United Kingdom $75.923B 9.52
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.436B 19.34
Arcus Biosciences (RCUS) United States $1.194B 0.00
Biohaven (BHVN) United States $0.913B 0.00
Emergent Biosolutions (EBS) United States $0.394B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
Enzo Biochem (ENZ) United States $0.106B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.012B 0.00